Displaying all 13 items
A British drug company has been fined $1 million for claims its painkiller products targeted particular parts of the body.
The Australian manufacturers of Nurofen painkillers will be fined $A6 million for 'inherently misleading' consumers, after an original fine of $A1.7m was increased on appeal.
The maker of Nurofen has been charged by the Commerce Commission for misleading the public about its "specific pain range". Audio
Nurofen is facing a number of charges over its labelling of pain products. Audio
The makers of Nurofen have been fined 1.7 million dollars by an Australian court but the consumer watchdog is arguing it's not enough. Audio
The maker of Nurofen should have to pay more than the $A1.7 million a court fined it for its misleading "specific pain range", says an Australian watchdog.
Nurofen medication targetting specific pain will no longer be sold in the current packaging after the company agreed it could be misleading. Audio
The company selling Nurofen medication in New Zealand will stop sales of its specific pain range products in their current packaging by March next year.
Lee Hohaia talks further about the facts and fallacies of "specific pain" Nurofen. Audio
Pharmacists will not be advised to remove some Nurofen products from shelves, but will ensure customers understand what they're buying. Audio
New Zealand needs to follow Australia and pull some Nurofen pain-relief products from the market, the Consumers' Institute says. Audio
Sue Chetwin is the head of the Consumer New Zealand. Audio
Nurofen made misleading claims about some of its products by advertising that they relieve specific types of pain, an Australian court has found.